A Phase II Randomized Controlled Study to Compare Endostar and IMRT vs. IMRT Alone for Locally Recurrent Nasopharyngeal Carcinoma Patients
Latest Information Update: 05 Jan 2023
At a glance
- Drugs Endostatin (Primary)
- Indications Nasopharyngeal cancer
- Focus Adverse reactions
- 31 Jan 2021 Planned End Date changed from 1 Dec 2019 to 1 Dec 2021.
- 31 Jan 2021 Status changed from recruiting to active, no longer recruiting.
- 08 Oct 2018 Planned End Date changed from 1 Dec 2018 to 1 Dec 2019.